Biological variation and hemoglobin A1c: Relevance to diabetes management and complications

Pediatric Diabetes

Volumn 14, Issue 6, 2013, Pages 391-398

  Chalew, Stuart A ^a   Mccarter, Robert J ^b   Hempe, James M ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Biological variation; Complications; HBA1c; Mean blood glucose

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE TRANSPORTER 1; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A; HEMOGLOBIN A1C; SCHIFF BASE;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN TENSION; PH; PRIORITY JOURNAL; REFERENCE VALUE; RETICULOCYTE COUNT; REVIEW;

BIOLOGICAL VARIATION; COMPLICATIONS; HBA1C; MEAN BLOOD GLUCOSE;

ADAPTATION, BIOLOGICAL; ADOLESCENT; ADOLESCENT DEVELOPMENT; CHILD; CHILD DEVELOPMENT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; STATISTICS AS TOPIC;

EID: 84882576465     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12055     Document Type: Review

References (70)

1. Fraser CG. Biological Variation: From Principles to Practice. Washington, DC: AACC Press, 2001.
2. Harris EK. Effects of intra- and interindividual variation on the appropriate use of normal ranges. Clin Chem 1974: 20: 1535-1542.
3. Lacher DA, Hughes JP, Carroll MD. Estimate of biological variation of laboratory analytes based on the third national health and nutrition examination survey. Clin Chem 2005: 51: 450-452.
4. Bunn HF. Evaluation of glycosylated hemoglobin in diabetic patients. Diabetes 1981: 30: 613-617.
5. Mortensen HB, Volund A, Christophersen C. Glucosylation of human haemoglobin A. Dynamic variation in HbA1c described by a biokinetic model. Clin Chim Acta 1984: 136: 75-81.
6. Smith RJ, Koenig RJ, Binnerts A, Soeldner JS, Aoki TT. Regulation of hemoglobin AIc formation in human erythrocytes in vitro. Effects of physiologic factors other than glucose. J Clin Invest 1982: 69: 1164-1168.
7. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta 1997: 260: 49-64.
8. Jain SK. Glutathione and glucose-6-phosphate dehydrogenase deficiency can increase protein glycosylation. Free Radic Biol Med 1998: 24: 197-201.
9. Kunika K, Itakura M, Yamashita K. Inorganic phosphate accelerates hemoglobin A1c synthesis. Life Sci 1989: 45: 623-630.
10. Hoelzel W, Miedema K. Development of a reference system for the international standardisation of HbA1c/glycohemoglobin determinations. J Int Fed Clin Chem 1996: 9: 62-67.
11. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976: 295: 417-420.
12. Paisey RB, Macfarlane DG, Sherriff RJ, Hartog M, Slade RR, White DA. The relationship between blood glycosylated haemoglobin and home capillary blood glucose levels in diabetics. Diabetologia 1980: 19: 31-34.
13. Svendsen PA, Lauritzen T, Soegaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in Type 1 (insulin-dependent) diabetes. Diabetologia 1982: 23: 403-405.
14. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care 1987: 10: 1-19.
15. Service FJ. Correlation between glycemia and glycated hemoglobin. Compr Ther 1990: 16: 33-40.
16. UK Prospective Diabetes Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998: 352: 837-853.
17. Hempe J, Gomez R, McCarter R, Chalew S. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications 2002: 16: 313-320.
18. Rohlfing CL, Wiedmeyer H, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c. Diabetes Care 2002: 25: 275-278.
19. Higgins T. HbA1c-an analyte of increasing importance. Clin Biochem 2012: 45: 1038-1045.
20. Cohen RM, Franco RS, Khera PK et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008: 112: 4284-4291.
21. Ramachandran A, Riddle MC, Kabali C, Gerstein HC. Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. Diabetes Care 2012: 35: 749-753.
22. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012: 97: 1067-1072.
23. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia 1990: 33: 208-215.
24. Kilpatrick ES, Maylor PW, Keevil BG. Biological variation of glycated hemoglobin. Implications for diabetes screening and monitoring. Diabetes Care 1998: 21: 261-264.
25. Rohlfing C, Wiedmeyer H, Little R et al. Biological variation of glycohemoglobin. Clin Chem 2002: 48: 1116-1118.
26. Braga F, Dolci A, Montagnana M et al. Revaluation of biological variation of glycated hemoglobin (HbA(1c)) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clin Chim Acta 2011: 412 (15-16): 1412-1416.
27. Carson AP, Fox CS, McGuire DK et al. Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes. Circ Cardiovasc Qual Outcomes 2010: 3: 661-667.
28. Aggarwal V, Schneider AL, Selvin E. Low hemoglobin A(1c) in nondiabetic adults: an elevated risk state? Diabetes Care 2012: 35: 2055-2060.
29. Madsen H, Kjaergaard JJ, Ditzel J. Relationship between glycosylation of haemoglobin and the duration of diabetes: a study during the third trimester of pregnancy. Diabetologia 1982: 22: 37-40.
30. Service FJ, O'Brien PC. Influence of glycemic variables on hemoglobin A1c. Endocr Pract 2007: 13: 350-354.
31. Herman WH, Dungan KM, Wolffenbuttel BH et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1, 5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009: 94: 1689-1694.
32. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in hemoglobin glycation predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004: 27: 1259-1264.
33. McCarter RJ, Hempe JM, Chalew SA. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 2006: 29: 352-355.
34. Soros AA, Chalew SA, McCarter RJ, Shepard R, Hempe JM. Hemoglobin glycation index: a robust measure of hemoglobin A1c bias in pediatric type 1 diabetes patients. Pediatr Diabetes 2010: 11: 455-461.
35. Wilson DM, Xing D, Cheng J et al. Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Care 2011: 34: 1315-1317.
36. Hempe JM, McCarter RJ, Chalew SA. Comment on: Wilson et al. Persistence of individual variations in glycated hemoglobin: analysis of data from the juvenile diabetes research foundation continuous glucose monitoring randomized trial. Diabetes Care 2011;34:1315-1317. Diabetes Care 2011: 34: e170.
37. Wilson DM. Kollman. Relationship of A1C to glucose concentrations in children with type 1 diabetes: assessments by high-frequency glucose determinations by sensors. Diabetes Care 2008: 31: 381-385.
38. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 2003: 26: 163-167.
39. Nayak AU, Holland MR, Macdonald DR, Nevill A, Singh BM. Evidence for consistency of the glycation gap in diabetes. Diabetes Care 2011: 34: 1712-1716.
40. Chalew SA, McCarter RJ, Thomas J, Thomson JL, Hempe JM. A comparison of the Glycosylation Gap and Hemoglobin Glycation Index in patients with diabetes. J Diabetes Complications 2005: 19: 218-222.
41. Snieder H, Sawtell PA, Ross L, Walker J, Spector TD, Leslie RDG. HbA1c levels are genetically determined even in type 1 diabetes: Evidence from healthy and diabetic twins. Diabetes 2001: 50: 2858-2863.
42. Paterson AD, Waggott D, Boright AP et al. A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes 2010: 59: 539-549.
43. Soranzo N, Sanna S, Wheeler E et al. Common variants at 10 genomic loci influence hemoglobin A1c levels via glycemic and nonglycemic pathways. Diabetes 2010: 59: 3229-3239.
44. Jansen H, Stolk RP, Nolte IM, Kema IP, Wolffenbuttel BH, Snieder H. Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their interactions in the lifelines cohort study. J Intern Med 2012: 273: 283-293.
45. Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 2009: 3: 635-643.
46. Nuttall FQ, Gannon MC, Swaim WR, Adams MJ. Stability over time of glycohemoglobin, glucose, and red blood cell survival in hematologically stable people without diabetes. Metabolism 2004: 53: 1399-1404.
47. Higgins PJ, Garlick RL, Bunn HF. Glycosylated hemoglobin in human and animal red cells. Role of glucose permeability. Diabetes 1982: 31: 743-748.
48. Bistritzer T, Roeder LM, Hanukoglu L, Levin PA. Non-insulin dependent diabetic patients have increased glucose uptake in red blood cells. Horm Metab Res 1991: 23: 70-73.
49. Khera PK, Joiner CH, Carruthers A et al. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 2008: 57: 2445-2452.
50. Szwergold BS, Beisswenger PJ. Enzymatic deglycaton-a new paradigm or an epiphenomenon? Biochem Soc Trans 2003: 31: 1428-1432.
51. Chalew SA, McCarter RJ, Ory-Ascani J, Hempe JM. Labile A1C is inversely correlated with the hemoglobin glycation index in children with type 1 diabetes. Diabetes Care 2010: 33: 273-274.
52. van Leiden HA, Dekker JM, Moll AC et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol 2003: 121: 245-251.
53. Selvin E, Ning Y, Steffes MW et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011: 60: 298-305.
54. Singer DE, Nathan DM, Keaven MA, Wilson PWF, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992: 41: 202-208.
55. Khaw KT, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001: 322: 15-18.
56. Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 2005: 28: 1981-1987.
57. Selvin E, Steffes MW, Zhu H et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010: 362: 800-811.
58. van 't Riet E, Rijkelijkhuizen JM, Alssema M et al. HbA1c is an independent predictor of nonfatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study. Eur J Cardiovasc Prev Rehabil 2012: 19: 23-31.
59. Lachin JM, Genuth S, Nathan DM, Rutledge BN. The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes 2007: 56: 1913-1921.
60. Rodriguez-Segade S, Rodriguez J, Cabezas-Agricola JM, Casanueva FF, Camina F. Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c). Clin Chem 2011: 57: 264-271.
61. Cosson E, Banu I, Cussac-Pillegand C et al. Glycation gap is associated with macroproteinuria but not with other complications in patients with type 2 diabetes. Diabetes Care 2013 [Epub ahead of print].
62. Sacks DB, Nathan DM, Lachin JM. Gaps in the glycation gap hypothesis. Clin Chem 2011: 57: 150-152.
63. Monnier VM, Sell DR, Dai Z, Nemet I, Collard F, Zhang J. The role of the Amadori product in the complications of diabetes. Ann N Y Acad Sci 2008: 1126: 81-88.
64. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994: 43: 836-841.
65. Cerami A. The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's. J Intern Med 2012: 271: 219-226.
66. Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005: 54: 3103-3111.
67. Felipe DL, Hempe JM, Liu S et al. Skin intrinsic fluorescence is associated with hemoglobin A1c and hemoglobin glycation index but not mean blood glucose in children with type 1 diabetes. Diabetes Care 2011: 34: 1816-1820.
68. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008: 31: 1473-1478.
69. Chalew SA, Hempe JM, McCarter R. Clinically significant disagreement between mean blood glucose and estimated average glucose in two populations: implications for diabetes management. J Diabetes Sci Technol 2009: 3: 1128-1135.
70. Hempe JM, Soros AA, Chalew SA. Estimated average glucose and self-monitored mean blood glucose are discordant estimates of glycemic control. Diabetes Care 2010: 33: 1449-1451.